ACRX - AcelRx Pharmaceuticals, Inc.
| Previous Close | 2.4800 |
| Open | 2.5800 |
| Bid | 2.40 x 2900 |
| Ask | 2.45 x 3000 |
| Day's Range | 2.4300 - 2.6500 |
| 52 Week Range | 1.6500 - 5.0500 |
| Volume | 2,137,727 |
| Avg. Volume | 2,925,532 |
| Market Cap | 191.748M |
| Beta (3Y Monthly) | 1.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.83 |
| Earnings Date | Oct 30, 2017 - Nov 3, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.42 |
- GlobeNewswire•11 days ago
Investor Expectations to Drive Momentum within PulteGroup, Dave & Buster's Entertainment, AcelRx Pharmaceuticals, LSC Communications, PNM Resources, Inc. (Holding Co.), and H&E Equipment Services — Discovering Underlying Factors of Influence
NEW YORK, Jan. 09, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•13 days ago
AcelRx Pharmaceuticals announces publication analyzing pooled data on sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain
- Over 800 patients from AcelRx studies supporting DSUVIA™ approval were included in the pooled safety analysis - Initial dosing of 30 mcg sufentanil sublingual tablet calculated as dose-equivalent to ...
- Motley Fool•24 days ago
2 Biotech Penny Stocks to Buy Right Now
AcelRx and Novavax are two penny biotech stocks worth checking out in this latest market downturn.
- Insider Monkey•27 days ago
Hedge Funds Are Crazy About AcelRx Pharmaceuticals Inc (ACRX)
Amid an overall market correction, many stocks that smart money investors were collectively bullish on tanked during the fourth quarter. Among them, Amazon and Netflix ranked among the top 30 picks and both lost around 20%. Facebook, which was the second most popular stock, lost 14% amid uncertainty regarding the interest rates and tech valuations. […]
- Zacks•last month
Implied Volatility Surging for AcelRx Pharmaceuticals (ACRX) Stock Options
Investors need to pay close attention to AcelRx Pharmaceuticals (ACRX) stock based on the movements in the options market lately.
- PR Newswire•last month
AcelRx Pharmaceuticals added to the NASDAQ Biotechnology Index (NBI)
REDWOOD CITY, Calif. , Dec. 18, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative ...
- Motley Fool•2 months ago
3 Stocks to Hold for the Next 20 Years
When you invest in a business, you should expect to stay with it for the long haul.
- PR Newswire•2 months ago
AcelRx Pharmaceuticals to Host Analyst and Investor Day on December 11
Update on DSUVIA U.S. commercialization strategy and insights from key healthcare professionals REDWOOD CITY, Calif. , Nov. 29, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), ...
- ACCESSWIRE•2 months ago
New Healthcare Trends Could Push Sector Stocks Higher
CORAL GABLES, FL / ACCESSWIRE / November 21, 2018 / Healthcare stocks continue to gain traction amid volatile market conditions this week. Investors have been less optimistic on tech stocks and more favorable to the healthcare sector. US midterm elections have also helped to boost a more favorable market for healthcare.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ACRX earnings conference call or presentation 5-Nov-18 1:30pm GMT
Q3 2018 AcelRx Pharmaceuticals Inc Earnings Call
- PR Newswire•2 months ago
AcelRx Pharmaceuticals to Present at the 17th Annual ASRA Pain Medicine Meeting
REDWOOD CITY, Calif. , Nov. 14, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
- Motley Fool•2 months ago
Here's Why AcelRx Pharmaceuticals Lost as Much as 18.4% Today
After earning FDA marketing approval for a controversial new drug, the company is raising cash through a share offering.
- PR Newswire•2 months ago
AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
REDWOOD CITY, Calif., Nov. 9, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) today announced the pricing of its previously announced underwritten public offering of 12,698,412 shares of its common stock, at a public offering price of $3.15 per share. All of the shares in the offering are to be sold by AcelRx. The offering is expected to close on or about November 14, 2018, subject to the satisfaction of customary closing conditions.
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind AcelRx Pharmaceuticals, Fossil Group, FMC, Ultragenyx Pharmaceutical, Shenandoah Telecommunications, and Marcus & Millichap — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•2 months ago
AcelRx Pharmaceuticals Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., Nov. 9, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. AcelRx expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. Credit Suisse Securities (USA) LLC, Jefferies LLC, Cantor Fitzgerald & Co. and RBC Capital Markets, LLC are acting as joint book-running managers for the offering.
- PR Newswire•2 months ago
AcelRx Pharmaceuticals to Present at Credit Suisse 27th Annual Healthcare Conference
REDWOOD CITY, Calif. , Nov. 7, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
- MarketWatch•2 months ago
Powerful new opioid 500 times stronger than morphine approved in U.S. in spite of outcry
Critics worried about putting such a potent and addictive medication on the market in the midst of the U.S.’s opioid crisis.
American City Business Journals•2 months agoHealth Care Digest: Health's push onto the ballot, an exec's cancer story and more
More health care issues are being decided at the ballot box, and Tuesday's election isn't the end of the trend.
- Motley Fool•2 months ago
Why AcelRx Pharmaceuticals Stock Is Slipping Today
Nothing to worry about after the biotech received a much-needed FDA approval last week.
- ACCESSWIRE•2 months ago
Monday's Top Healthcare Stocks To Watch Ahead Of Elections
Healthcare has become the latest market to take full advantage of this trend. According to a paper by PwC called The Digital Healthcare Leap, the new trends are ripe for digital healthcare solutions in developed and emerging markets. As a result, the industry has expanded its focus to non-critical health care services to cater to this changing demand of present-day consumers.
- ACCESSWIRE•2 months ago
Today’s Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and Sage Therapeutics
NEW YORK, NY / ACCESSWIRE / November 5, 2018 / AcelRx Pharmaceuticals saw big gains this past Friday after announcing third quarter results and an update on DSUVIA receiving FDA approval. Shares of Sage Therapeutics were halted after its treatment Zulresso, was recommended by an FDA approval for postpartum depression. AcelRx Pharmaceuticals, Inc. shares closed up 15.66% on about 20 million shares traded on Friday.
InvestorPlace•2 months ago3 Big Stock Charts for Monday: Coca-Cola, Kinder Morgan and Adobe
Headed into today’s action following Friday’s mostly uncommitted action, stock charts of Coca-Cola (NYSE:KO), Kinder Morgan (NYSE:KMI) and Adobe (NASDAQ:ADBE) are shaping up as your best trading bets. Coca-Cola shares had been trapped in a trading range as of August, but that range was finally broken this week. • In the weekly timeframe we can see a long-term trading range has also guided Coca-Cola shares upward since 2013.
- The Wall Street Journal•3 months ago
Noting Military Potential, FDA Approves Powerful Painkiller Dsuvia
The Food and Drug Administration on Friday approved a powerful new opioid drug called Dsuvia that has possible uses for treating wounded soldiers on the battlefield. Consumer representatives say the drug is especially potent and particularly susceptible to abuse. Balancing those dangers against needs for powerful painkillers in certain settings has been a dilemma for the FDA amid a national overdose epidemic.
- Zacks•3 months ago
AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -5.00% and -65.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
AcelRx Pharmaceuticals: 3Q Earnings Snapshot
On a per-share basis, the Redwood City, California-based company said it had a loss of 21 cents. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...
